Shah Gilani's Archive

Plug Power Inc. (NasdaqCM:PLUG) reports earnings this Thursday, May 20, 2021, after the bell. If the company disappoints on their numbers the stock could tumble.

In this week’s BS.H, I’m tackling three noxious stocks – stocks considered Wall Street darlings just because they were in the right place at the right time – that have many investors hook, line, and sinker.

But don’t be fooled, no matter how clean they look on the outside, these stocks are as toxic as they come. If you own one of these, you need to think about selling immediately and don’t look back.

Click the video below to find out just which stocks could be holding you back.

Just click here to get started…

The number of stocks in the psychedelics space, no pun intended, is expanding like all good universes.

There are already more than 50 publicly traded companies pursuing the billions in new market opportunities in the hallucinogen-based treatment market – a “New Biotech” opportunity I like to refer to as the ‘Shroom Boom.

A lot of these companies are innovative cousins to conventional biotech firms. Like their better-known counterparts, these upstarts are pursuing new drugs, compounds, therapies, and treatment protocols, to arrest or even cure mental illnesses, substance abuse, pain, PTSD, and even chronic brain disorders. The big difference: These ‘Shroom Boom ventures are incorporating psychedelics in their research and trials.

I’ve also identified “pick-and-shovel” companies whose path to sales-and-profits relies on sourcing and manufacturing psychedelics or building infrastructure, like clinics and training therapists.

Here are four companies I like. Two cover the research, trials, and biotech potential of psychedelics. The other two are pick-and-shovels plays that have ID’d innovative ways to apply their trade on this new trend.

In the entire realm of biotech, it’s one of the most-exciting and biggest-profit opportunities I’m watching.

I came of age in the late ’60s and early ’70s, which means I’m no stranger to recreational drugs, from pot to psychedelics. Like, I’ve seen things, man – and could tell you some stories. And I was so fascinated by what I saw that I got with the program, and dug deep into the story behind the story.

LSD was still legal. Research was going full bore. And I understood these drugs had promise – real promise.

That all ended in October 1968, when the U.S. made it illegal to possess the hallucinogen. And thanks to that, the research slowly died.

But psychedelics are making a comeback. And I’m groovin’ on all the hip research and FDA trials, and the crazy number of publicly traded companies chasing riches in the psychedelics rainbow.

Can you dig it? You should. There’s evidence psychedelics have the potential to arrest – and maybe even cure – a host of disorders from depression to brain trauma. And if these drugs work – and if you’re into the right stocks – you could end up on the trip of your life, and watch as your portfolio gets high … and I mean really high, man.

If you’re watching the markets and looking at this “new biotech,” you’re no doubt hearing about the tremendous promise of the marijuana legalization, the cannabis market – and the pot-stock boom.

Maybe you missed the pot-stock run the first time around. Or maybe you can’t bring yourself to invest in something in something that’s been maligned so much for so many years.

Don’t sweat it – because here’s the heavy truth: The real opportunity is with psychedelics.

Call it the Shroom Boom.

And I’m going to lay it on you here…

Last Tuesday, I mentioned I liked buying the MRNA June 18, 2021 $165/170 Put Spread to take advantage of what looked like an opportunity for a quick reversal in Moderna, Inc. (NasdaqGS:MRNA).

By Thursday, just two days later, shares of MRNA had dropped as much as 23%, and the MRNA June 18, 2021 $165/170 Put Spread had gained more than 400%

I sure hope you were following along!

Now I don’t mean to say, “I told you so,” but Varney & Co. didn’t call me the “Man Who Calls It All” for nothing. Just as I predicted a few months back, Pfizer (PFE) stands to lose its COVID-19 vaccine patents and their company’s profitability is about to tank. Hard.

That’s leaves us a wide opening to make some serious profits with its downfall, but that’s not all on my watchlist today.

Early this morning, you should have gotten my watchlist update. Those will be coming in hot every Monday before the opening bell, so make sure to keep your eyes peeled!

If you missed it, don’t worry. You can read all about my favorite stocks for the week here.

Or, just click the video below because I am back with yet another video to take an even deeper dive into these stocks. PFE may be on its way out, but two other heavy-hitting Chinese stocks, NIO and BABA, are going to take off before the year is out.

So, let’s get started…

Tech stocks own the market, but that doesn’t mean you should go blindly into them. That’s what most people will do – but you shouldn’t.

Putting the hype before the horse means you’ll almost always wind up with losers disguised as the next Amazon. So, in today’s BS.H, you’ll hear about three tech stocks that run the gauntlet from the good, the bad, and the exceptionally ugly. I go over their profits, their debts, and whether they’re fit to buy, sell, or hold.

Just click the video below to watch…

With COVID-19 vaccination programs rolling along, it might well be assumed that any stock tied to vaccinations is on a one-way trip higher.

Not so fast. There’s that whole thing about “assuming,” and I think you know what they say…

With legalization around the corner for so many states in the U.S., several of you were asking: “To buy or not to buy?”

That is the question… A few years back I would have given a resounding heck no. But I have to say, I’m starting to change my mind about two of the biggest pot stocks on the market right now.

And I’ll tell you why in today’s BS.H, where I tell you what to buy, sell, or hold.

Been to the grocery store lately? Then you know that food prices are surging.

The U.S. Federal Reserve refers to that as “inflation” – a clinical bit of jargon that fails to capture the sticker-shock pain your family feels every time you wheel a shopping cart into the checkout line.

Central bankers also tell us this inflation is “transitory.”

But I’m here to tell you that it’s not.

Food prices have been rising for almost two years; they really accelerated during the pandemic and have never looked back.

And it’s only going to get worse.

Thanks to surging demand both here and overseas, the multi-year “Megadrought” in the southwestern United States, an ongoing “overhang” from the COVID-19 pandemic, and foreign-trade gamesmanship from Beijing, agricultural commodities are soaring in price.

Just look at the “Big Three” of ag commodities – wheat, corn, and soybeans.

Wheat, the key ingredient in flour, bread, cookies, pastries, and pasta was already at a seven-year high – and just logged its biggest weekly climb in almost two years on expectations of strong global demand and lower production from Russia, the world’s No. 1 exporter. Cold temperatures have hit winter wheat crops in the Southern Plains and Central states of America. And, according to FranceAgriMer’s cereal crop report, France’s wheat and barley crops have deteriorated, too.

Corn, which goes into cereals, snack foods, soft drinks, and other sweet foods, is already at its highest level since 2013 – thanks to lousy weather that’s delayed planting in such crucial growing regions like the United States and Brazil. The U.S. Department of Agriculture said that cold weather could slow the germination of newly seeded corn. U.S. corn crop was 8% planted as of Apr 18. The crops from the 2020 harvest have also been deteriorating.

Finally, we have soybeans, used in soymilk, tofu, and as protein for cattle – meaning they influence meat prices. Soybeans are brushing up against eight-year highs. Tightening global grain and vegetable oil supplies just ignited the biggest weekly rise in soybean futures since May 2019. Meanwhile, the Chinese are trying to import more soybeans to meet strong demand from that country’s livestock sector. And shipments from Brazil – the world’s top exporter – dropped to their lowest level since January 2017. The Farm Bureau says cool, dry weather in the Midwest could hurt soybean crops, although U.S. farmers plan to plant 87.6 million acres of soybeans this year – the most since 2018 – to capitalize on that demand and the higher prices the supply squeeze will create.

So, yes that basket of groceries you’re bringing home to your family will continue to take bigger and bigger bites out of your household budget.

Here’s why I’m sharing this all with you today.

I’m decoding the ag-commodity surge, explaining the inflationary spike still to come, and identifying some of the companies that stand to be the biggest beneficiaries. You can buy these shares, ride along as they profit – and make enough to transform food-price inflation into a non-factor in your household.

And I mean starting today. Starting right now…